XBiotech Inc. (Nasdaq: XBIT) said its upcoming presentation of pivotal Phase III data for Xilonix, the Company’s lead therapy developed ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE